This newfound understanding not only broadens our comprehension of DPP-4 inhibitor actions but also underscores the multifaceted nature of therapeutic interventions targeting peripheral neuropathies in the diabetic milieu, paving the way for nuanced approaches aimed at mitigating neuropathic complications beyond conventional glycemic control strategies. The gene discussed is DPP4; the disease is peripheral neuropathy.